Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > New Press Release - Voyageur Commences Testing of Innovative Barium Contrast Product Line in Human Radiology Scans, Paving the Way for Near-Term Market Launch
View:
Comment by lscfa on Jan 13, 2025 11:35am
Sept 05, 2024 -  The patient trials are anticipated to take approximately two months, encompassing comprehensive analyses of imaging scans and the preparation of independent white papers for each product. All testing is following guidelines for future FDA licensing. Brent Willis, CEO of Voyageur, explains, "Voyageur highlights that transitioning from generic formulations to a more ...more  
Comment by lscfa on Jan 13, 2025 6:27pm
What the hell is the business plan here? Sell barium contrast products at a loss to gain market share until they build their own mining and processing facilities?
Comment by biggdogg on Jan 13, 2025 7:07pm
You must be new?? They have always stated they are starting with contract manufacturer to prove economics. That way they don't have to build pilot plant for FC. A great strategy, and they do make money, just not 70% margins. After sales, feasibility is proven. It also allows their product line to establish market growth, further show casing the $344m valuation. 
Comment by lscfa on Jan 13, 2025 7:13pm
VM is going to import barium sulphate from China, same as others do, so no cost advantage until they build their own mine/plant. 
Comment by JrOGInvestor on Jan 13, 2025 10:13pm
They don't need to build a min, it's akin to a gravel pit. They don't need to build their own plant if the deal with 'Big Pharma' gives them access to cash to get something already built and tweak it. 
Comment by postie1 on Jan 14, 2025 8:03am
Yes, I do believe it is a quarry pit permit. If i recall properly there is some sort of processor to be built on site. The manufacturing will be elsewhere
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1